Synlait Milk Shares Jump on Asset Sale to Abbott and Narrowed Loss

Synlait Milk (NZ:SML) shares surged on Monday after the New Zealand dairy company reported a smaller annual loss and announced a major asset sale to global healthcare leader Abbott. The agreement, valued at about NZ$307 million (US$176.8 million), involves the sale of Synlait’s North Island operations, including its Pokeno factory, blending and canning facilities, and warehousing. The transaction is expected to close by April 2026, pending regulatory and shareholder approval.

For the year ended July 31, Synlait posted a net loss after tax of NZ$39.8 million, significantly reduced from the NZ$182.1 million loss recorded a year earlier. The company also reported an underlying net profit of NZ$0.8 million, reversing a NZ$60.4 million deficit from the prior year. Management attributed the turnaround to stronger performances across its advanced nutrition, ingredients, and consumer divisions, which boosted profit margins.

Proceeds from the Abbott deal will primarily be used to cut Synlait’s debt, a move supported by its majority shareholder, Bright Dairy, which has already pledged backing for the transaction. Following the sale, Synlait plans to focus on its South Island operations as part of its broader strategic reset.

Despite the improved results, Synlait declined to provide earnings guidance for FY26, citing the scale of its restructuring. Investors, however, responded positively to the update. Shares of Synlait surged as much as 21% to NZ$0.845, marking their highest level in nearly six months.

The Abbott partnership not only strengthens Synlait’s financial position but also positions the company to streamline its business model and concentrate resources on its most profitable segments. Analysts say the move reflects a necessary shift for the dairy processor as it works to rebuild confidence among shareholders and regain growth momentum in a competitive global dairy market.